Moberg Derma Discontinues Clinical Development of Limtop  
3/11/2013 11:08:05 AM

STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Moberg Derma AB (STO:MOB) has decided to discontinue the development of Limtop - a drug candidate for the treatment of actinic keratosis. The decision is based on data from a completed phase II clinical trial, where the efficacy of Limtop did not reach the predefined target. "Based on data from the completed study, we deem that the project's commercial potential has decreased and that continued investment therefore is not justified. This does not affect the company's assessment for continued profitable growth during 2013," said Peter Wolpert, President and CEO of Moberg Derma AB.